On the other hand, novel strategies aimed at modulating Hippo pathway activity or disrupting YAP–TEAD interactions are currently under investigation and may offer a path toward personalized treatment approaches in aggressive breast cancer subtypes [25,26]. This evidence concerns the gene YAP1 and breast cancer.